Skip to main content

Table 4 Anthropometric and Biochemical Characteristics of the participants at Baseline and by week 24

From: Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial

 

Pioglitazone Group

Empagliflozin Group

 

Variables

Baseline

(n = 36)

After 24 weeks

(n = 36)

P value

Baseline

(n = 37)

After 24 weeks

(n = 37)

P**value

P* value between groups

BMI (kg/m2)

31.3 ± 5.0

32.1 ± 5.3

0.01

31.0 ± 3.8

29.8 ± 3.6

< 0.01

< 0.01

FBS (mg/dl)

165 ± 49

130 ± 34

< 0.01

177 ± 66

141 ± 46

0.01

0.92

HbA1c (%)

8.4 ± 1.1

7.0 ± 1.1

< 0.01

8.6 ± 1.1

7.2 ± 1.0

< 0.01

0.78

TG (mg/dl)

212.8 ± 127.9

139.4 ± 69.4

< 0.01

161.7 ± 70.6

143.8 ± 83.2

0.21

0.04

Tchol (mg/dl)

158.3 ± 32.4

162.6 ± 34.3

0.56

146.0 ± 30.3

147.6 ± 35.4

0.83

0.79

LDL (mg/dl)

100.1 ± 20.6

83.8 ± 26.9

< 0.01

96.3 ± 26.0

74.5 ± 21.6

< 0.01

0.44

HDL (mg/dl)

46.7 ± 9.3

55.6 ± 9.5

< 0.01

44.8 ± 8.9

46.0 ± 7.5

0.31

< 0.01

ALT (IU/L)

31.5 ± 12.2

21.0 ± 8.6

< 0.01

31.8 ± 17.6

22.2 ± 11.0

< 0.01

0.76

AST (IU/L)

23.0 ± 7.7

19.5 ± 6.5

< 0.01

25.1 ± 14.5

18.8 ± 5.8

< 0.01

0.23

TyG*

9.6 ± 0.6

9.0 ± 0.6

< 0.01

9.4 ± 0.7

9.1 ± 0.6

0.01

0.16

NAFLD fibrosis score

-1.3 ± 0.9

-0.7 ± 1.0

< 0.01

-1.2 ± 0.8

− 0.9 ± 0.8

0.04

0.04

FIB4 index

0.9 ± 0.4

1.0 ± 0.4

0.15

0.9 ± 0.4

0.9 ± 0.3

0.49

0.13

  1. ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; CAP, controlled attenuation parameter; FBS, fasting blood sugar; FIB4 index, fibrosis-index; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LSM, Liver stiffness measurement; NAFLD fibrosis score, non-alcoholoic fatty liver score; Tchol, total Cholesterol; TG, Triglycerides
  2. * Triglyceride-glucose index (TyG) = Ln [FBS (mg/dl) × TG (mg/dl)/2]
  3. TyG index has been proposed as a numerical expression of insulin resistance (IR)
  4. **P value < 0.05 is considered as significant.
  5. *Between-group difference from the baseline, P value < 0.05 is considered as significant.
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us